| Variables . | Level . | Clopidogrel (n = 443) . | Ticagrelor (n = 660) . | Prasugrel (n = 291) . |
|---|---|---|---|---|
| Sex, n (%) | Male | 261 (58.9) | 408 (61.8) | 198 (68.0) |
| Female | 182 (41.1) | 252 (38.2) | 93 (32.0) | |
| Age, years | Median (IQR) | 78 (70–84) | 76 (68–81) | 68 (61–75) |
| Weight, kg | Mean (SD) | 74.4 (16.6) | 76.1 (16.1) | 78.7 (16.7) |
| Comorbidities | ||||
| Hypertension | n (%) | 281 (63.4) | 341 (51.7) | 140 (48.1) |
| Hypercholesterolaemia | 173 (39.1) | 218 (33.0) | 116 (39.9) | |
| Diabetes | 79 (17.8) | 93 (14.1) | 37 (12.7) | |
| Heart failure | 81 (18.3) | 73 (11.1) | 49 (16.8) | |
| Cardiac arrhythmia | 130 (29.3) | 88 (13.3) | 53 (18.2) | |
| Chronic renal failure | 43 (9.7) | 43 (6.5) | 18 (6.2) | |
| Bleeding events | 163 (36.8) | 195 (29.5) | 126 (43.3) | |
| Peptic ulcer | 35 (7.9) | 31 (4.7) | 13 (4.5) | |
| Cancer | 79 (17.8) | 108 (16.4) | 42 (14.4) | |
| Stroke | 59 (13.3) | 29 (4.4) | 4 (1.4) | |
| Prior drug use | ||||
| Acetylsalicylic acid | n (%) | 131 (29.6) | 162 (24.5) | 81 (27.8) |
| Any P2Y12 inhibitor | 29 (6.5) | 31 (4.7) | 14 (4.8) | |
| Anticoagulants | 68 (15.3) | 17 (2.6) | 9 (3.1) | |
| NSAID | 103 (23.3) | 156 (23.6) | 71 (24.4) | |
| Oral steroids | 43 (9.7) | 62 (9.4) | 17 (5.8) | |
| Percutaneous coronary intervention (PCI) | ||||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 45 (10.2) | 62 (9.4) | 41 (14.1) |
| Minutes from symptoms to PCI | Median (IQR) | 201 (136–299) | 183 (128–285) | 153 (118–262) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 45 (32.6) | 65 (23.6) | 31 (38.3) |
| >35% | 93 (67.4) | 211 (76.4) | 50 (61.7) | |
| Killip class, n (%) | >II | 18 (4.3) | 14 (2.2) | 5 (1.8) |
| I–II | 404 (95.7) | 618 (97.8) | 275 (98.2) | |
| Infarct location, n (%) | Anterior | 191 (47.0) | 265 (43.4) | 123 (44.4) |
| Non-anterior | 215 (53.0) | 345 (56.6) | 154 (55.6) | |
| Culprit, n (%) | LM/LAD | 203 (46.1) | 279 (42.5) | 130 (44.8) |
| RCA | 179 (40.7) | 279 (42.5) | 127 (43.8) | |
| CX | 58 (13.2) | 99 (15.1) | 33 (11.4) | |
| Pre-TIMI, n (%) | 0–I | 288 (65.9) | 393 (60.1) | 171 (59.4) |
| II–III | 149 (34.1) | 261 (39.9) | 117 (40.6) | |
| Post-TIMI, n (%) | 0–I | 13 (3.0) | 9 (1.4) | 4 (1.4) |
| II–III | 422 (97.0) | 642 (98.6) | 283 (98.6) | |
| Intervention, n (%) | Drug eluting stent | 249 (57.1) | 530 (81.0) | 221 (76.2) |
| Bare metal stent | 58 (13.3) | 11 (1.7) | 9 (3.1) | |
| Stent unknown | 31 (7.1) | 0 (0.0) | <4 (<1.4) | |
| Balloon angioplasty only | 98 (22.5) | 113 (17.3) | 58 (20.0) | |
| Lesions, n (%) | 1 lesion | 359 (81.8) | 537 (81.6) | 231 (79.7) |
| ≥2 lesions | 79 (18.0) | 120 (18.2) | 59 (20.3) | |
| Implanted stents, n (%) | None | 103 (23.7) | 115 (17.5) | 59 (20.6) |
| 1 stent | 278 (64.1) | 451 (68.8) | 210 (73.2) | |
| ≥2 stents | 53 (12.2) | 90 (13.7) | 18 (6.3) | |
| Revascularization degree according to the operator, n (%) | Complete | 247 (56.8) | 384 (58.7) | 178 (61.4) |
| Incomplete–deferred | 85 (19.5) | 178 (27.2) | 68 (23.4) | |
| Incomplete–finished | 103 (23.7) | 92 (14.1) | 44 (15.2) | |
| Drugs within 7 days from discharge | ||||
| Acetylsalicylic acid | n (%) | 333 (75.2) | 542 (82.1) | 240 (82.5) |
| Anticoagulants | 82 (18.5) | 9 (1.4) | 8 (2.7) | |
| Proton-pump inhibitors | 137 (30.9) | 164 (24.8) | 53 (18.2) | |
| Treatment duration with first claimed P2Y12 inhibitor, n (%) | ≤6 months | 54 (12.2) | 160 (24.2) | 38 (13.1) |
| 6–12 months | 389 (87.8) | 500 (75.8) | 253 (86.9) | |
| Variables . | Level . | Clopidogrel (n = 443) . | Ticagrelor (n = 660) . | Prasugrel (n = 291) . |
|---|---|---|---|---|
| Sex, n (%) | Male | 261 (58.9) | 408 (61.8) | 198 (68.0) |
| Female | 182 (41.1) | 252 (38.2) | 93 (32.0) | |
| Age, years | Median (IQR) | 78 (70–84) | 76 (68–81) | 68 (61–75) |
| Weight, kg | Mean (SD) | 74.4 (16.6) | 76.1 (16.1) | 78.7 (16.7) |
| Comorbidities | ||||
| Hypertension | n (%) | 281 (63.4) | 341 (51.7) | 140 (48.1) |
| Hypercholesterolaemia | 173 (39.1) | 218 (33.0) | 116 (39.9) | |
| Diabetes | 79 (17.8) | 93 (14.1) | 37 (12.7) | |
| Heart failure | 81 (18.3) | 73 (11.1) | 49 (16.8) | |
| Cardiac arrhythmia | 130 (29.3) | 88 (13.3) | 53 (18.2) | |
| Chronic renal failure | 43 (9.7) | 43 (6.5) | 18 (6.2) | |
| Bleeding events | 163 (36.8) | 195 (29.5) | 126 (43.3) | |
| Peptic ulcer | 35 (7.9) | 31 (4.7) | 13 (4.5) | |
| Cancer | 79 (17.8) | 108 (16.4) | 42 (14.4) | |
| Stroke | 59 (13.3) | 29 (4.4) | 4 (1.4) | |
| Prior drug use | ||||
| Acetylsalicylic acid | n (%) | 131 (29.6) | 162 (24.5) | 81 (27.8) |
| Any P2Y12 inhibitor | 29 (6.5) | 31 (4.7) | 14 (4.8) | |
| Anticoagulants | 68 (15.3) | 17 (2.6) | 9 (3.1) | |
| NSAID | 103 (23.3) | 156 (23.6) | 71 (24.4) | |
| Oral steroids | 43 (9.7) | 62 (9.4) | 17 (5.8) | |
| Percutaneous coronary intervention (PCI) | ||||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 45 (10.2) | 62 (9.4) | 41 (14.1) |
| Minutes from symptoms to PCI | Median (IQR) | 201 (136–299) | 183 (128–285) | 153 (118–262) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 45 (32.6) | 65 (23.6) | 31 (38.3) |
| >35% | 93 (67.4) | 211 (76.4) | 50 (61.7) | |
| Killip class, n (%) | >II | 18 (4.3) | 14 (2.2) | 5 (1.8) |
| I–II | 404 (95.7) | 618 (97.8) | 275 (98.2) | |
| Infarct location, n (%) | Anterior | 191 (47.0) | 265 (43.4) | 123 (44.4) |
| Non-anterior | 215 (53.0) | 345 (56.6) | 154 (55.6) | |
| Culprit, n (%) | LM/LAD | 203 (46.1) | 279 (42.5) | 130 (44.8) |
| RCA | 179 (40.7) | 279 (42.5) | 127 (43.8) | |
| CX | 58 (13.2) | 99 (15.1) | 33 (11.4) | |
| Pre-TIMI, n (%) | 0–I | 288 (65.9) | 393 (60.1) | 171 (59.4) |
| II–III | 149 (34.1) | 261 (39.9) | 117 (40.6) | |
| Post-TIMI, n (%) | 0–I | 13 (3.0) | 9 (1.4) | 4 (1.4) |
| II–III | 422 (97.0) | 642 (98.6) | 283 (98.6) | |
| Intervention, n (%) | Drug eluting stent | 249 (57.1) | 530 (81.0) | 221 (76.2) |
| Bare metal stent | 58 (13.3) | 11 (1.7) | 9 (3.1) | |
| Stent unknown | 31 (7.1) | 0 (0.0) | <4 (<1.4) | |
| Balloon angioplasty only | 98 (22.5) | 113 (17.3) | 58 (20.0) | |
| Lesions, n (%) | 1 lesion | 359 (81.8) | 537 (81.6) | 231 (79.7) |
| ≥2 lesions | 79 (18.0) | 120 (18.2) | 59 (20.3) | |
| Implanted stents, n (%) | None | 103 (23.7) | 115 (17.5) | 59 (20.6) |
| 1 stent | 278 (64.1) | 451 (68.8) | 210 (73.2) | |
| ≥2 stents | 53 (12.2) | 90 (13.7) | 18 (6.3) | |
| Revascularization degree according to the operator, n (%) | Complete | 247 (56.8) | 384 (58.7) | 178 (61.4) |
| Incomplete–deferred | 85 (19.5) | 178 (27.2) | 68 (23.4) | |
| Incomplete–finished | 103 (23.7) | 92 (14.1) | 44 (15.2) | |
| Drugs within 7 days from discharge | ||||
| Acetylsalicylic acid | n (%) | 333 (75.2) | 542 (82.1) | 240 (82.5) |
| Anticoagulants | 82 (18.5) | 9 (1.4) | 8 (2.7) | |
| Proton-pump inhibitors | 137 (30.9) | 164 (24.8) | 53 (18.2) | |
| Treatment duration with first claimed P2Y12 inhibitor, n (%) | ≤6 months | 54 (12.2) | 160 (24.2) | 38 (13.1) |
| 6–12 months | 389 (87.8) | 500 (75.8) | 253 (86.9) | |
Missing: LVEF (37%), Killip class (2%), infarct location (4%).
CX, circumflex coronary artery; LAD, left anterior descending coronary artery; LM, left main coronary artery; NSAID, non-steroidal anti-inflammatory drugs; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
| Variables . | Level . | Clopidogrel (n = 443) . | Ticagrelor (n = 660) . | Prasugrel (n = 291) . |
|---|---|---|---|---|
| Sex, n (%) | Male | 261 (58.9) | 408 (61.8) | 198 (68.0) |
| Female | 182 (41.1) | 252 (38.2) | 93 (32.0) | |
| Age, years | Median (IQR) | 78 (70–84) | 76 (68–81) | 68 (61–75) |
| Weight, kg | Mean (SD) | 74.4 (16.6) | 76.1 (16.1) | 78.7 (16.7) |
| Comorbidities | ||||
| Hypertension | n (%) | 281 (63.4) | 341 (51.7) | 140 (48.1) |
| Hypercholesterolaemia | 173 (39.1) | 218 (33.0) | 116 (39.9) | |
| Diabetes | 79 (17.8) | 93 (14.1) | 37 (12.7) | |
| Heart failure | 81 (18.3) | 73 (11.1) | 49 (16.8) | |
| Cardiac arrhythmia | 130 (29.3) | 88 (13.3) | 53 (18.2) | |
| Chronic renal failure | 43 (9.7) | 43 (6.5) | 18 (6.2) | |
| Bleeding events | 163 (36.8) | 195 (29.5) | 126 (43.3) | |
| Peptic ulcer | 35 (7.9) | 31 (4.7) | 13 (4.5) | |
| Cancer | 79 (17.8) | 108 (16.4) | 42 (14.4) | |
| Stroke | 59 (13.3) | 29 (4.4) | 4 (1.4) | |
| Prior drug use | ||||
| Acetylsalicylic acid | n (%) | 131 (29.6) | 162 (24.5) | 81 (27.8) |
| Any P2Y12 inhibitor | 29 (6.5) | 31 (4.7) | 14 (4.8) | |
| Anticoagulants | 68 (15.3) | 17 (2.6) | 9 (3.1) | |
| NSAID | 103 (23.3) | 156 (23.6) | 71 (24.4) | |
| Oral steroids | 43 (9.7) | 62 (9.4) | 17 (5.8) | |
| Percutaneous coronary intervention (PCI) | ||||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 45 (10.2) | 62 (9.4) | 41 (14.1) |
| Minutes from symptoms to PCI | Median (IQR) | 201 (136–299) | 183 (128–285) | 153 (118–262) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 45 (32.6) | 65 (23.6) | 31 (38.3) |
| >35% | 93 (67.4) | 211 (76.4) | 50 (61.7) | |
| Killip class, n (%) | >II | 18 (4.3) | 14 (2.2) | 5 (1.8) |
| I–II | 404 (95.7) | 618 (97.8) | 275 (98.2) | |
| Infarct location, n (%) | Anterior | 191 (47.0) | 265 (43.4) | 123 (44.4) |
| Non-anterior | 215 (53.0) | 345 (56.6) | 154 (55.6) | |
| Culprit, n (%) | LM/LAD | 203 (46.1) | 279 (42.5) | 130 (44.8) |
| RCA | 179 (40.7) | 279 (42.5) | 127 (43.8) | |
| CX | 58 (13.2) | 99 (15.1) | 33 (11.4) | |
| Pre-TIMI, n (%) | 0–I | 288 (65.9) | 393 (60.1) | 171 (59.4) |
| II–III | 149 (34.1) | 261 (39.9) | 117 (40.6) | |
| Post-TIMI, n (%) | 0–I | 13 (3.0) | 9 (1.4) | 4 (1.4) |
| II–III | 422 (97.0) | 642 (98.6) | 283 (98.6) | |
| Intervention, n (%) | Drug eluting stent | 249 (57.1) | 530 (81.0) | 221 (76.2) |
| Bare metal stent | 58 (13.3) | 11 (1.7) | 9 (3.1) | |
| Stent unknown | 31 (7.1) | 0 (0.0) | <4 (<1.4) | |
| Balloon angioplasty only | 98 (22.5) | 113 (17.3) | 58 (20.0) | |
| Lesions, n (%) | 1 lesion | 359 (81.8) | 537 (81.6) | 231 (79.7) |
| ≥2 lesions | 79 (18.0) | 120 (18.2) | 59 (20.3) | |
| Implanted stents, n (%) | None | 103 (23.7) | 115 (17.5) | 59 (20.6) |
| 1 stent | 278 (64.1) | 451 (68.8) | 210 (73.2) | |
| ≥2 stents | 53 (12.2) | 90 (13.7) | 18 (6.3) | |
| Revascularization degree according to the operator, n (%) | Complete | 247 (56.8) | 384 (58.7) | 178 (61.4) |
| Incomplete–deferred | 85 (19.5) | 178 (27.2) | 68 (23.4) | |
| Incomplete–finished | 103 (23.7) | 92 (14.1) | 44 (15.2) | |
| Drugs within 7 days from discharge | ||||
| Acetylsalicylic acid | n (%) | 333 (75.2) | 542 (82.1) | 240 (82.5) |
| Anticoagulants | 82 (18.5) | 9 (1.4) | 8 (2.7) | |
| Proton-pump inhibitors | 137 (30.9) | 164 (24.8) | 53 (18.2) | |
| Treatment duration with first claimed P2Y12 inhibitor, n (%) | ≤6 months | 54 (12.2) | 160 (24.2) | 38 (13.1) |
| 6–12 months | 389 (87.8) | 500 (75.8) | 253 (86.9) | |
| Variables . | Level . | Clopidogrel (n = 443) . | Ticagrelor (n = 660) . | Prasugrel (n = 291) . |
|---|---|---|---|---|
| Sex, n (%) | Male | 261 (58.9) | 408 (61.8) | 198 (68.0) |
| Female | 182 (41.1) | 252 (38.2) | 93 (32.0) | |
| Age, years | Median (IQR) | 78 (70–84) | 76 (68–81) | 68 (61–75) |
| Weight, kg | Mean (SD) | 74.4 (16.6) | 76.1 (16.1) | 78.7 (16.7) |
| Comorbidities | ||||
| Hypertension | n (%) | 281 (63.4) | 341 (51.7) | 140 (48.1) |
| Hypercholesterolaemia | 173 (39.1) | 218 (33.0) | 116 (39.9) | |
| Diabetes | 79 (17.8) | 93 (14.1) | 37 (12.7) | |
| Heart failure | 81 (18.3) | 73 (11.1) | 49 (16.8) | |
| Cardiac arrhythmia | 130 (29.3) | 88 (13.3) | 53 (18.2) | |
| Chronic renal failure | 43 (9.7) | 43 (6.5) | 18 (6.2) | |
| Bleeding events | 163 (36.8) | 195 (29.5) | 126 (43.3) | |
| Peptic ulcer | 35 (7.9) | 31 (4.7) | 13 (4.5) | |
| Cancer | 79 (17.8) | 108 (16.4) | 42 (14.4) | |
| Stroke | 59 (13.3) | 29 (4.4) | 4 (1.4) | |
| Prior drug use | ||||
| Acetylsalicylic acid | n (%) | 131 (29.6) | 162 (24.5) | 81 (27.8) |
| Any P2Y12 inhibitor | 29 (6.5) | 31 (4.7) | 14 (4.8) | |
| Anticoagulants | 68 (15.3) | 17 (2.6) | 9 (3.1) | |
| NSAID | 103 (23.3) | 156 (23.6) | 71 (24.4) | |
| Oral steroids | 43 (9.7) | 62 (9.4) | 17 (5.8) | |
| Percutaneous coronary intervention (PCI) | ||||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 45 (10.2) | 62 (9.4) | 41 (14.1) |
| Minutes from symptoms to PCI | Median (IQR) | 201 (136–299) | 183 (128–285) | 153 (118–262) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 45 (32.6) | 65 (23.6) | 31 (38.3) |
| >35% | 93 (67.4) | 211 (76.4) | 50 (61.7) | |
| Killip class, n (%) | >II | 18 (4.3) | 14 (2.2) | 5 (1.8) |
| I–II | 404 (95.7) | 618 (97.8) | 275 (98.2) | |
| Infarct location, n (%) | Anterior | 191 (47.0) | 265 (43.4) | 123 (44.4) |
| Non-anterior | 215 (53.0) | 345 (56.6) | 154 (55.6) | |
| Culprit, n (%) | LM/LAD | 203 (46.1) | 279 (42.5) | 130 (44.8) |
| RCA | 179 (40.7) | 279 (42.5) | 127 (43.8) | |
| CX | 58 (13.2) | 99 (15.1) | 33 (11.4) | |
| Pre-TIMI, n (%) | 0–I | 288 (65.9) | 393 (60.1) | 171 (59.4) |
| II–III | 149 (34.1) | 261 (39.9) | 117 (40.6) | |
| Post-TIMI, n (%) | 0–I | 13 (3.0) | 9 (1.4) | 4 (1.4) |
| II–III | 422 (97.0) | 642 (98.6) | 283 (98.6) | |
| Intervention, n (%) | Drug eluting stent | 249 (57.1) | 530 (81.0) | 221 (76.2) |
| Bare metal stent | 58 (13.3) | 11 (1.7) | 9 (3.1) | |
| Stent unknown | 31 (7.1) | 0 (0.0) | <4 (<1.4) | |
| Balloon angioplasty only | 98 (22.5) | 113 (17.3) | 58 (20.0) | |
| Lesions, n (%) | 1 lesion | 359 (81.8) | 537 (81.6) | 231 (79.7) |
| ≥2 lesions | 79 (18.0) | 120 (18.2) | 59 (20.3) | |
| Implanted stents, n (%) | None | 103 (23.7) | 115 (17.5) | 59 (20.6) |
| 1 stent | 278 (64.1) | 451 (68.8) | 210 (73.2) | |
| ≥2 stents | 53 (12.2) | 90 (13.7) | 18 (6.3) | |
| Revascularization degree according to the operator, n (%) | Complete | 247 (56.8) | 384 (58.7) | 178 (61.4) |
| Incomplete–deferred | 85 (19.5) | 178 (27.2) | 68 (23.4) | |
| Incomplete–finished | 103 (23.7) | 92 (14.1) | 44 (15.2) | |
| Drugs within 7 days from discharge | ||||
| Acetylsalicylic acid | n (%) | 333 (75.2) | 542 (82.1) | 240 (82.5) |
| Anticoagulants | 82 (18.5) | 9 (1.4) | 8 (2.7) | |
| Proton-pump inhibitors | 137 (30.9) | 164 (24.8) | 53 (18.2) | |
| Treatment duration with first claimed P2Y12 inhibitor, n (%) | ≤6 months | 54 (12.2) | 160 (24.2) | 38 (13.1) |
| 6–12 months | 389 (87.8) | 500 (75.8) | 253 (86.9) | |
Missing: LVEF (37%), Killip class (2%), infarct location (4%).
CX, circumflex coronary artery; LAD, left anterior descending coronary artery; LM, left main coronary artery; NSAID, non-steroidal anti-inflammatory drugs; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
